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4-Phosphothiophen-2-yl alanine: a new
5-membered analogue of phosphotyrosine†
Matthew Lilley,ab Bezaleel Mambwe,b Richard F. W. Jackson*a and
Richmond Muimo*b
Polyclonal antibodies raised against 4-phosphothiophen-2-yl alanine
2a, a novel five-membered ring analogue of phosphotyrosine,
showed high selectivity for phosphotyrosine and no cross-reactivity
with other phosphorylated amino acids. Western blots showed that
the polyclonal was similarly eﬀective, but diﬀerent in selectivity, to a
commercially available monoclonal antibody.
Protein tyrosine phosphatases (PTPs) catalyse the dephosphoryl-
ation of phosphotyrosine residues and together with protein
tyrosine kinases (PTKs) regulate the tyrosine phosphoproteome
in cells.1 Several PTPs have been identified as attractive thera-
peutic targets in human diseases such as cancer, diabetes,
obesity, neurodegenerative disorders and inflammation.2–4
Since phosphotyrosine 1 is unstable under typical biological
conditions, interest in the biological roles of PTPs concomitantly
led to the development of stable analogues of phosphotyrosine.4,5
These analogues, azobenzene phosphonate (ABP),6 phospho-
tyramine,7 phosphonomethylphenylalanine (Pmp),8 and difluoro-
phosphono-methylphenylalanine (F2Pmp)9,10 have been invaluable
tools in unraveling the importance of phosphotyrosine in cellular
processes. These benzenoid analogues have been useful not
only as immunogens to generate antibodies that recognise
phosphotyrosine with high specificity without cross-reactivity
to other phosphoamino acids, but also as inhibitors and
aﬃnity ligands for PTPs and other pTyr binding proteins.
Significantly, incorporation of Pmp and F2Pmp into peptide
sequences, has provided phospho-site specific antibodies and
more potent or specific phosphatase inhibitors. These peptides
have also been used as aﬃnity ligands and in structural studies
where they have provided invaluable information about protein–
protein interactions.8–11 A major limitation is the absence of
specific inhibitors against many PTPs. Consequently, PTP research
has lagged behind PTK studies and the related field of serine/
threonine protein phosphatases.12,13
Motivated by a report on the corresponding furan 2b that
suggested it might be a non-hydrolysable and non-isomerisable
analogue of phosphohistidine 3,14 we synthesised 4-phospho-
thiophen-2-yl alanine, 2a, with the aim of establishing whether
the thiophene would better mimic the imidazole in 3 or the
benzene ring in 1. Hirao cross coupling15 between diethyl
phosphite and 3-bromothiophene gave 3-diethoxylphosphothio-
phene 4. Iodination of 4 gave, in addition to the 2,5-diodo-
derivative (18%), the iodothiophene 5, which was subjected to
Negishi cross-coupling with zinc reagent 6 using our recently
optimised conditions16 to give the protected amino acid 7.
Sequential deprotection then gave 4-phosphothiophen-2-yl ala-
nine 2a, via the corresponding acid 8 (Scheme 1).
Scheme 1 Synthesis of 4-phosphothiophen-2-yl alanine 2a.
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To explore its potential as a phosphoamino acid analogue,
compound 2a was used as a hapten to produce antibodies.
Polyclonal antibodies were raised in rats using KLH-conjugated
analogue 2a as the immunogen. In one of the initial reports of a
phosphotyrosine antibody generated using ABP as immunogen,
Frackelton et al. observed cross-reactivity towards phospho-
histidine 3.6 In the course of this study, several non-hydrolysable
analogues of phosphohistidine have been reported including
phosphopyrrole,17 phosphoryltriazolylalanine isomers,18,19 a
sulfonamide-based transition-state analogue of enzymatic
phosphohistidine dephosphorylation20 and phosphoryltriazolyl-
ethylamine.21 Use of phosphoryltriazolylalanine as a mimic of
one phosphohistidine in a histone H4 peptide allowed the
generation of antibodies that did not universally recognise
phosphohistidine in proteins.18 Antibodies subsequently
generated to phosphoryltriazolylethylamine showed cross-reactivity
towards phosphohistidine and phosphotyrosine.21 The reactiv-
ity of the antibodies generated to 2a was initially tested using
dot-blots spotted with BSA-conjugated histidine, phosphoserine,
phosphothreonine, phosphotyrosine and t-phosphohistidine.
Antibodies showed strong reactivity towards phosphotyrosine
without any cross-reactivity for t-phosphohistidine, histidine,
tyrosine or other phosphohydroxy amino acids (results not
shown). This suggested that 2a was a potential analogue for
phosphotyrosine. The antibodies were therefore rescreened
against tyrosine, phosphotyrosine, phosphoserine, phospho-
threonine and t-phosphohistidine (Fig. 1, entry A). The anti-
bodies showed high selectivity for phosphotyrosine with minimal
side reactivity towards BSA-conjugated t-phosphohistidine (Fig. 1,
A lane v). However, this apparent t-phosphohistidine cross-
reactivity was simply removed by aﬃnity depletion using a
histidine–KLH glutaraldehyde conjugated Sepharose column
(Fig. 1, entry B) suggesting that the cross linker itself produced
a reasonable immune response.
The thiophene in analogue 2a is evidently a poor mimic of
the corresponding imidazole present in t-phosphohistidine, but
a good mimic of the benzene ring present in phosphotyrosine,
which has resulted in a polyclonal serum that detects phospho-
tyrosine in preference to t-phosphohistidine.
Competition studies, performed by ELISA on the purified
polyclonal antibody, showed no binding or inhibition of the
antisera by any of the amino acids apart from phosphotyrosine
(Fig. 2). This indicates that while analogue 2a may not be a
suitable analogue for t-phosphohistidine it was likely to be a
useful analogue for phosphotyrosine. Competitive inhibition
ELISA analysis using O-phospho-L-tyrosine (pTyr) or 2a, demon-
strated that the antibody generated from 2a has a higher
aﬃnity towards 2a compared to phosphotyrosine (Fig. 3, see
inset), as expected.
In Western blot analysis, using cytosolic fractions obtained
from sheep tracheal epithelia, the antibody generated from 2a
gave a staining profile comparable to that of a commercially
available anti-phosphotyrosine monoclonal antibody (pY99) –
albeit with varying degrees of staining or detection intensity
for various protein bands by either antibody (Fig. 4A). This
indicates that the antibody generated by 2a is able to detect
phosphotyrosine containing proteins and recognises many protein
bands that are also detected by the anti-phosphotyrosine pY99.
Interestingly, the antibody generated from 2a also detected pro-
teins that were not detected by the pY99 (and vice versa). This is
consistent with previous studies where different types of anti-
bodies provided varied results in the same systems.22
Furthermore, in total lysates of human bronchial epithelial
cell lines (16HBE14o-) treated with Na3VO4 (a broad spectrum
PTP inhibitor) for 45 min, both the antibody generated from 2a
and pY99 detect enhanced phosphorylation of a high molecular
Fig. 1 Dot-blots of 4-phosphothiophen-2-yl alanine generated antibody
using (A) crude polyclonal antibody and (B) polyclonal antibody aﬃnity
depleted with Sepharose bound/glutaraldehyde linked histidine–KLH when
probed for (i) tyrosine, (ii) phosphotyrosine, (iii) phosphoserine, (iv) phospho-
threonine, (v) t-phosphohistidine, (vi) 4-phosphothiophen-2-yl alanine.
Fig. 2 Competitive inhibition ELISA study using anti-sera generated from
4-phosphothiophen-2-yl alanine, 2a.
Fig. 3 A competitive inhibition ELISA study involving O-phospho-L-
tyrosine (pTyr) and 4-phosphothiophen-2-yl alanine, 2a using anti-sera
generated from analogue, 2a.
Communication ChemComm
Pu
bl
ish
ed
 o
n 
30
 Ju
ne
 2
01
4.
 D
ow
nl
oa
de
d 
by
 U
ni
ve
rs
ity
 o
f S
he
ffi
el
d 
on
 1
8/
07
/2
01
4 
14
:3
2:
56
. 
View Article Online
This journal is©The Royal Society of Chemistry 2014 Chem. Commun.
weight protein (Fig. 4B, filled arrow). However, pY99 additionally
detects enhanced phosphorylation of three other proteins (approx.
75, 100, 180 kDa) in Na3VO4 treated cells (Fig. 4B, left panel, unfilled
arrow heads). Interestingly, both antibodies also detect several other
proteins that were insensitive to Na3VO4 and in this regard, pY99
antibodies detected two, whereas the antibody generated from 2a
detected six, of these proteins. In lysates from cells stimulated with
epidermal growth factor (EGF, 1 nM for 4 hours), both the antibody
generated from 2a and pY99 detected enhanced phosphorylation of
a high molecular weight protein (Fig. 4C, filled arrow).
In conclusion, we have synthesized 4-phosphothiophen-2-yl
alanine, 2a and demonstrated its potential as a novel 5-membered
ring analogue of phosphotyrosine. Our data suggests that
analogue 2a, and resulting polyclonal antibody, may potentially
be a useful tool to both characterize the biological eﬀects of
phosphotyrosine and the role of specific PTP(s) in cells.
We thank the EPSRC Life Sciences Interface DTC (ML). The
16HBE14o- cells were provided by Dr D. Gruenert (California
Pacific Medical Center, CA).
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Fig. 4 Comparison of antibody generated to 2a and commercially avail-
able anti-phosphotyrosine monoclonal antibody (pY99). (A) Western blots
of cytosolic fraction from sheep tracheal epithelia probed with pY99 or 2a
antibody. Arrows highlight similarities (filled) or diﬀerences (unfilled). Western
blots of lysates of human bronchial epithelial cell lines (16HBE14o-) treated
Na3VO4 (10 mM) for 45 min (B) or EGF (1 nM) for 4 hours (C) and probed
with pY99 (left panel) or the antibody generated from 2a (right panel),
(C = control, untreated). Arrows/arrowheads highlight similarities (filled) or
diﬀerences (unfilled).
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